Ip. Bissett et al., Results of extrafascial excision and conventional surgery for rectal cancer at Auckland Hospital, AUST NZ J S, 70(10), 2000, pp. 704-709
Background: Recent studies have suggested that local recurrence rates follo
wing rectal cancer surgery are reduced if the mesorectum is removed intact
within its fascia propria. The present study aims to compare the outcomes o
f conventional surgery for rectal cancer and surgery in which the rectum an
d mesorectum are removed by the technique of extrafascial excision (EFE).
Methods: All patients undergoing surgery for rectal cancer at Auckland Hosp
ital from 1980 to 1996 were identified. Demographic, tumour, operation, out
come, survival and follow-up data were obtained from patient charts, New Ze
aland (NZ) Death Registry, death-certificates and the NZ Electoral Roll. Co
mplication rates, recurrence rates, overall and cancer-free survival and tr
eatment costs were calculated for each group.
Results: A total of 262 patients had curative surgery (138 had conventional
surgery, 124 had EFE). The groups were similar with respect to age, sex, o
peration performed and Dukes' stage. There was no difference in complicatio
n rates between the groups. Mean follow-up was 7 years in survivors. Twenty
-nine conventional-surgery (21%) and eight EFE (6%) patients developed loca
l pelvic recurrence. The 5-year actuarial local recurrence rates were 30% a
nd 10%, respectively (P = 0.0006). The 5-year overall survival was 54% for
conventional surgery and 60% for EFE (P = 0.23). The 5-year cancer-free sur
vival was 63% for conventional surgery and 74% for EFE (P = 0.02). Average
initial costs were NZ$15 717 and NZ$15 158 for conventional surgery and EFE
, respectively. The average cost of local recurrence was an additional NZ$1
0 471.
Conclusions: The present study adds further support to the growing evidence
that excision of the mesorectum within an intact fascial envelope reduces
local recurrence rates after surgery for rectal cancer. There appears to be
an associated improvement in cancer-free survival. Complication rates and
cost were not increased in the patients having EFE.